Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Targeting TIGIT and PD-1 in solid tumors

Meredith McKean • 22 Oct 2023
ESMO 2023
General
ACTIVATE

Meredith McKean, MD, MPH, Sarah Cannon Research Institute, London, UK, provides an overview of developments in TIGIT as a target in solid tumors. Numerous anti-TIGIT have been previously assessed and the Phase Ib/II ACTIVATE trial (NCT04761198) will investigate TIGIT inhibition with PD-1 inhibition. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Meredith McKean

1:09
Darovasertib and crizotinib in uveal melanoma
Meredith McKean • 22 Oct 2023
0:42
ACTIVATE: etigilimab and nivolumab in locally advanced/metastatic solid tumors
Meredith McKean • 22 Oct 2023
1:09
DRAGON: SRK-181 alone/in combination with anti-PD-L1 treatment in patients with advanced solid tumor
Meredith McKean • 9 Nov 2021
0:54
NEON-1 & NEON-2: ALPN-202 alone or with pembrolizumab in patients with advanced malignancies
Meredith McKean • 9 Nov 2021

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals